Matinas BioPharma to Present at Biotech Showcase 2024
BEDMINSTER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) — Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining […]
Acreage Enters New York Adult-Use Market with First Wholesale Product Sale
The Botanist products expected to hit participating adult-use dispensary shelves the week of January 8th Full menu of The Botanist […]
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation […]
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
FOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical […]
Important Update on Listing Status and Strategic Direction
Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) — Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily […]
Asensus Surgical, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) — Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company […]
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company […]
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
– In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown – – All Evaluable […]
NIO Inc. Announces Repurchase Right Notification for 0.00% Convertible Senior Notes due 2026
SHANGHAI, China, Jan. 03, 2024 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), […]
Ragnarok X : Next Genration Received a ISBN Code by Chinese Government
Seoul, Jan. 03, 2024 (GLOBE NEWSWIRE) — GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher of […]
